Newer mechanical devices in the management of acute heart failure.
Heart Failure is the only cardiovascular disease diagnosis increasing in prevalence in the United States. Currently there are more than 5 million people diagnosed with heart failure in the United States and that population is increasing exponentially. Clinical trials in advanced pharmacological therapies have shown a significant value in reducing the morbidity and mortality of the disease process. Nevertheless, many patients who are optimally treated with drug therapy continue to progress from asymptomatic left ventricular dysfunction to symptomatic and then end-stage heart failure. Beyond drug therapy, devices have begun to make a significant impact on symptoms and clinical outcomes in patients, particularly those with more advanced forms of heart failure. New technologies being investigated include destination and bridge LV assist devices. Due to the invasive nature of these devices a new generation of "less invasive" percutaneous devices are now being studied. These new generation devices offer the promise of improved LV function and an enhanced neurohormonal profile for the failing ventricle, thus improving the quality of life in the ever-burgeoning heart failure population.
Mather
Paul J
PJ
Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA, USA. paul.mather@jefferson.edu
Konstam
Marvin A
MA
D000208:Acute Disease; D002986:Clinical Trials as Topic; D004867:Equipment Design; D006333:Heart Failure / Q000628:therapy*; D006353:Heart-Assist Devices; D006801:Humans